Immunohistochemistry of pulmonary biomarkers : a perspective from members of the pulmonary pathology society
The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK, (ROS1, EGFR in Europe), and programmed death ligand-1 (PD-L1) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes.
© 2018 College of American Pathologists
2018
2020-12-17 09:03:44
1033
pulmonary biomarkers, immunohistochemistry, pathology
pljučni biomarkerji, imunohistokemija, patologija
College of American Pathologists
Erik
Thunnissen
70
Timothy Craig
Allen
70
Julien
Adam
70
Dara L.
Aisner
70
Mary Beth
Beasley
70
Alain C.
Borczuk
70
Philip T.
Cagle
70
Vera Luiza
Capelozzi
70
Wendy
Cooper
70
Izidor
Kern
70
UDK
4
616.2
ISSN pri članku
9
0003-9985
DOI
15
10.5858/arpa.2017-0106-SA
COBISS_ID
3
33522905
OceCobissID
13
253975
0
Izvorni URL
2020-12-17 09:03:48